{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:13:32Z","timestamp":1788300812227,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["FWO G0G4220N"],"award-info":[{"award-number":["FWO G0G4220N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018214","name":"Belgische Federale Overheidsdiensten","doi-asserted-by":"publisher","award":["COVID-19_SC117"],"award-info":[{"award-number":["COVID-19_SC117"]}],"id":[{"id":"10.13039\/100018214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018214","name":"Belgische Federale Overheidsdiensten","doi-asserted-by":"publisher","award":["COVID-19_SC059"],"award-info":[{"award-number":["COVID-19_SC059"]}],"id":[{"id":"10.13039\/100018214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018214","name":"Belgische Federale Overheidsdiensten","doi-asserted-by":"publisher","award":["COVID-19_SC004"],"award-info":[{"award-number":["COVID-19_SC004"]}],"id":[{"id":"10.13039\/100018214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018214","name":"Belgische Federale Overheidsdiensten","doi-asserted-by":"publisher","award":["COVID-19_SC096"],"award-info":[{"award-number":["COVID-19_SC096"]}],"id":[{"id":"10.13039\/100018214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018214","name":"Belgische Federale Overheidsdiensten","doi-asserted-by":"publisher","award":["COVID-19_SC095"],"award-info":[{"award-number":["COVID-19_SC095"]}],"id":[{"id":"10.13039\/100018214","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128897","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:09:12Z","timestamp":1783112952000},"page":"128897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial"],"prefix":"10.1016","volume":"89","author":[{"given":"St\u00e9phanie","family":"Depick\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Pannus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Heyndrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9e","family":"Georges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Verbrugghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desombere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Ari\u00ebn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128897_bb0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128897_bb0010","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/vaccines11111720","article-title":"Dynamics of serum-neutralizing antibody responses in vaccinees through multiple doses of the BNT162b2 vaccine","volume":"11","author":"Sheehan","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128897_bb0015","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128897_bb0020","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2195786","article-title":"Vaccine co-administration in adults: an effective way to improve vaccination coverage","volume":"19","author":"Bonanni","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128897_bb0025","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/08971900221081621","article-title":"Barriers to COVID-19 vaccines and strategies to improve acceptability and uptake","volume":"36","author":"Nawas","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.vaccine.2026.128897_bb0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08830185.2022.2079642","article-title":"SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies","volume":"42","author":"Gong","year":"2023","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128897_bb0035","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(22)00075-4","article-title":"COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness","volume":"10","author":"Roozen","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128897_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1087138","article-title":"The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries","volume":"10","author":"Duroseau","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.128897_bb0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/fvl-2021-0280","article-title":"Myocarditis and COVID-19 Mrna vaccines: a mechanistic hypothesis involving dsRNA","volume":"17","author":"Milano","year":"2022","journal-title":"Fut Virol"},{"key":"10.1016\/j.vaccine.2026.128897_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/vaccines8030404","article-title":"COVID-19: mechanisms of vaccination and immunity","volume":"8","author":"Speiser","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128897_bb0055","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","article-title":"A survey of COVID-19 vaccine acceptance across 23 countries in 2022","volume":"29","author":"Lazarus","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128897_bb0060","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116932119","article-title":"Testing fractional doses of COVID-19 vaccines","volume":"119","author":"Wi\u0119cek","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128897_bb0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.medj.2023.02.001","article-title":"Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India","volume":"4","author":"Du","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.vaccine.2026.128897_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-011881","article-title":"Vaccine access, equity and justice: COVID-19 vaccines and vaccination","volume":"8","author":"Privor-Dumm","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2026.128897_bb0075","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.vaccine.2022.03.036","article-title":"A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines","volume":"40","author":"Nanthapisal","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128897_bb0080","unstructured":"WHO. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. World Health Organ n.d. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know (accessed February 10, 2025)."},{"key":"10.1016\/j.vaccine.2026.128897_bb0085","article-title":"Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomized, double-blind, phase IV clinical trial in Brazil","author":"Puga","year":"2024","journal-title":"Lancet Reg Health - Am"},{"key":"10.1016\/j.vaccine.2026.128897_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.07.018","article-title":"Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: the IMCOVAS randomized clinical trial","volume":"42","author":"Steenackers","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128897_bb0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1473-3099(22)00800-3","volume":"23","author":"Fadlyana","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128897_bb0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jinf.2022.04.018","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2026.128897_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002703","article-title":"Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants","volume":"4","author":"Riou","year":"2024","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128897_bb0110","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128897_bb0115","article-title":"The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series","author":"Angkasekwinai","year":"2022","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.vaccine.2026.128897_bb0120","article-title":"Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial","volume":"42","author":"Batmunkh","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2026.128897_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2233400","article-title":"Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: a phase 4, single-blind, randomized controlled trial in adults","volume":"19","author":"Costa Clemens","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128897_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijid.2023.01.022","article-title":"Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and omicron variants","volume":"129","author":"Niyomnaitham","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128897_bb0135","article-title":"Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population","volume":"9","author":"Intapiboon","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128897_bb0140","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2022.08.033","article-title":"Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine","volume":"40","author":"Kanokudom","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128897_bb0145","article-title":"Immunogenicity and safety of half-dose heterologous mRNA-1273 booster vaccination for adults primed with the CoronaVac\u00ae and ChAdOx1-S vaccines for SARS-CoV-2","volume":"12","author":"Putri","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128897_bb0150","article-title":"A randomized clinical trial of a fractional low dose of BNT162b2 booster in adults following AZD1222","volume":"10","author":"Nantanee","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128897_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001308","article-title":"Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial","volume":"2","author":"Pannus","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128897_bb0160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128897_bb0165","unstructured":"Greg Snow. blockrand: randomization for block random clinical trials. R package v 1.5; 2020."},{"key":"10.1016\/j.vaccine.2026.128897_bb0170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.vaccine.2026.128897_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.vaccine.2026.128897_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126544","article-title":"COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients","volume":"44","author":"Gemander","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128897_bb0185","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1093\/cid\/ciab998","article-title":"Poor antibody response to BioNTech\/Pfizer coronavirus disease 2019 vaccination in severe acute respiratory syndrome coronavirus 2\u2013naive residents of nursing homes","volume":"75","author":"Pannus","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128897_bb0190","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128897_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/v14102301","article-title":"Two years of genomic surveillance in Belgium during the SARS-CoV-2 pandemic to attain country-wide coverage and monitor the introduction and spread of emerging variants","volume":"14","author":"Cuypers","year":"2022","journal-title":"Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:22:37Z","timestamp":1788297757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S0264410X26007061"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128897","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128897"}}